PhaseBio Pharmaceuticals, Inc.
NASDAQ: PHAS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan Mow
- Employees
- 60
- Headquarters
- Malvern, United States
- IPO year
- 2018
- Website
- https://phasebio.com
Loading PHAS…
Loading profile data…Frequently asked questions about PHAS
What does PhaseBio Pharmaceuticals, Inc. (PHAS) do?
PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the...
Where does PHAS trade?
PhaseBio Pharmaceuticals, Inc. (PHAS) trades on the NASDAQ Global Market.
What sector is PHAS in?
PhaseBio Pharmaceuticals, Inc. (PHAS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PhaseBio Pharmaceuticals, Inc.?
Jonathan Mow is the chief executive officer of PhaseBio Pharmaceuticals, Inc. (PHAS).
Where is PhaseBio Pharmaceuticals, Inc. headquartered?
PhaseBio Pharmaceuticals, Inc. is headquartered in United States.
Does PHAS pay a dividend?
PhaseBio Pharmaceuticals, Inc. (PHAS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHAS go public?
PhaseBio Pharmaceuticals, Inc. (PHAS) completed its initial public offering in 2018.